Although gender differences in cancer genetics are recognized in other malignancies, LSCC-specific studies have not reported these genetic patterns such as the mutations of CDK8 in females and ATP8B1 in males, warranting further investigation to determine if these could serve as sex-specific therapeutic targets or biomarkers. This evidence concerns the gene CDK8 and cancer.